These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 21612875)
41. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Diel IJ; Cote RJ Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491 [TBL] [Abstract][Full Text] [Related]
42. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Callejo SA; Antecka E; Blanco PL; Edelstein C; Burnier MN Eye (Lond); 2007 Jun; 21(6):752-9. PubMed ID: 16575415 [TBL] [Abstract][Full Text] [Related]
43. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies. Poste G Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734 [TBL] [Abstract][Full Text] [Related]
44. [Detection, characterization and clinical significance of circulating cancer cells in patients surgically treated for breast cancer]. Giarnieri E; De Francesco GP; Carico E; Falasca C; Marino G; Catracchia V; Midiri G; Amanti C; Giovagnoli MR; Angelini L G Chir; 2004 May; 25(5):194-8. PubMed ID: 15382481 [TBL] [Abstract][Full Text] [Related]
45. Cancer stemness and metastasis: therapeutic consequences and perspectives. Monteiro J; Fodde R Eur J Cancer; 2010 May; 46(7):1198-203. PubMed ID: 20303259 [TBL] [Abstract][Full Text] [Related]
46. Cancer. Fusion for moving. Clawson GA Science; 2013 Nov; 342(6159):699-700. PubMed ID: 24202164 [No Abstract] [Full Text] [Related]
47. The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Hemmings C Pathology; 2010 Feb; 42(2):105-12. PubMed ID: 20085510 [TBL] [Abstract][Full Text] [Related]
48. [Minimal metastatic and minimal residual disease in patients with Ewing tumors]. Zoubek A; Pfleiderer C; Ambros PF; Kronberger M; Dworzak MN; Gruber B; Luegmayer A; Windhager R; Fink FM; Urban C Klin Padiatr; 1995; 207(4):242-7. PubMed ID: 7564161 [TBL] [Abstract][Full Text] [Related]
49. Epigenetic and Pluripotency Aspects of Disseminated Cancer Cells During Minimal Residual Disease. Carlini MJ; Shrivastava N; Sosa MS Adv Exp Med Biol; 2018; 1100():1-18. PubMed ID: 30411257 [TBL] [Abstract][Full Text] [Related]
55. Immune dysfunction, minimal residual disease and patient outcome in nonmetastatic cancer: could modulation of immune function improve outcome? Murray NP Future Oncol; 2021 May; 17(13):1571-1575. PubMed ID: 33626930 [No Abstract] [Full Text] [Related]
56. Tumor cell detection in peripheral blood and bone marrow. Zach O; Lutz D Curr Opin Oncol; 2006 Jan; 18(1):48-56. PubMed ID: 16357564 [TBL] [Abstract][Full Text] [Related]
57. Minimal residual neoplastic disease--concept, pathogenesis, and supplementary therapeutic possibilities. Prindull G Cancer Treat Rev; 1986 Sep; 13(3):177-94. PubMed ID: 3536089 [No Abstract] [Full Text] [Related]
58. Tumour microenvironment: informing on minimal residual disease in solid tumours. Pantel K; Alix-Panabières C Nat Rev Clin Oncol; 2017 Jun; 14(6):325-326. PubMed ID: 28397823 [No Abstract] [Full Text] [Related]
59. Metastasis awakening: the challenges of targeting minimal residual cancer. Polzer B; Klein CA Nat Med; 2013 Mar; 19(3):274-5. PubMed ID: 23467237 [No Abstract] [Full Text] [Related]
60. Dormant Cells: The Original Cause of Tumor Recurrence and Metastasis. Li J; Jiang E; Wang X; Shangguan AJ; Zhang L; Yu Z Cell Biochem Biophys; 2015 Jun; 72(2):317-20. PubMed ID: 25556072 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]